Pharmaceutical giant Roche has appointed Cohn & Wolfe to handle PR
for a drug to tackle heart problems.
The agency has won two separate pitches, gaining the worldwide account,
excluding North America, and also the UK account, to promote
The newly-created UK account was awarded following a three-way
Account director Shairoe Ebrahim leads a three-strong team and reports
to Roche PR executive Susie Hackett.
The international account was won following a two-way pitch against
Countrywide Porter Novelli.
C&W director Fiona McMillan leads a five-strong team from the agency's
London base and reports to international communication manager, Annette
Walz, who is based in Basel, Switzerland.
Medical Action Communications previously handled the account but Yunus
Jaleel, Roche international business leader, said the decision to
appoint C&W made sense due to its global reach.
He said: 'MAC did a great job, but we needed a bigger push, which is
something that Cohn & Wolfe can provide.'
The account wins make C&W the global agency for Carvedilol, as its New
York office has handled the US PR effort for the last three years.
In the US, the drug is produced by GlaxoSmithKline and called Coreg.
In the UK, it is known as Eucardic and across the Continent, it is known
The treatment is a beta-blocking agent used to treat heart failure,
hypertension and angina.